ASCO 2016 | Targeted therapy for advanced solid tumors based on molecular profiles: early results from MyPathway
Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Get great new content delivered to your inboxSign up
The LUNAR study: TTFields for NSCLC
Tumor treating fields as an anti-mitotic therapy
Patient impact: development of drugs to treat METex14 alterations
Tepotinib: advanced non-small cell lung cancer
Future treatment options for squamous cell lung cancer